BRISBANE, Calif., June 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that John Hodgman, Senior Vice President and Chief Financial Officer of InterMune, will present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference in Dana Point, Calif. on June 10, 2008 at 8:05 a.m. PDT (11:05 a.m. EDT). Mr. Hodgman will also present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference in New York on June 12, 2008 at 9:30 a.m. EDT.
To access a live audio webcast of either presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentations in order to register or download any necessary software.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved